11.5 C
New York
Wednesday, February 8, 2023

What Are The Chances Of X4 Pharmaceuticals Inc. (NASDAQ: XFOR) Becoming A Clear Buy?

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for X4 Pharmaceuticals Inc. (XFOR) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.01, or -0.83%, to $1.20. The X4 Pharmaceuticals Inc. has recorded 3,779 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Stocks Info

As a NASDAQ listed company, XFOR falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $1.21 and fluctuated between $1.2600 as its day high and $1.1600 as its day low. The current market capitalization of X4 Pharmaceuticals Inc. is $147.70M. A total of 0.92 million shares were traded on the day, compared to an average of 1.28M shares.

In the most recent transaction, Ragan Paula sold 6,292 shares of XFOR for 1.21 per share on Jun 03. After the transaction, the President and CEO now owns 661,806 company shares.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for XFOR in the last 3 months, the mean price target is $4.79 with high estimates of $7.00 and low estimates of $3.00. In terms of 52-week highs and lows, XFOR has a high of $2.41 and a low of $0.65.

As of this writing, XFOR has an earnings estimate of -$0.3 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.23 per share and a lower estimate of -$0.46. The company reported an EPS of -$0.72 in the last quarter, which was -18.00% lower than expectations of -$0.61.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 8 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for XFOR is Overweight with a score of 5.00. A total of 8 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles